{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T04:23:46Z","timestamp":1772079826002,"version":"3.50.1"},"reference-count":34,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.3892\/mmr.2013.1413","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T08:01:24Z","timestamp":1365062484000},"page":"1723-1725","source":"Crossref","is-referenced-by-count":26,"title":["Targeting the A3 adenosine receptor for glaucoma treatment (Review)"],"prefix":"10.3892","volume":"7","author":[{"given":"PNINA","family":"FISHMAN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHIRA","family":"COHEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SARA","family":"BAR-YEHUDA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2013,4,4]]},"reference":[{"key":"key20180109222643_b1-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ajo.2011.06.004","article-title":"An assessment of the health and economic burdens of glaucoma","volume":"152","author":"Varma","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"key20180109222643_b2-mmr-07-06-1723","first-page":"299","article-title":"Adenosine, tumors and immunity","volume-title":"Adenosine Receptors: Therapeutic Aspects for Inflammatory and Immune Diseases","author":"Fishman","year":"2007"},{"key":"key20180109222643_b3-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1002\/jnr.21071","article-title":"Activation of adenosine A3 receptors reduces ischemic brain injury in rodents","volume":"84","author":"Chen","year":"2006","journal-title":"J Neurosci Res"},{"key":"key20180109222643_b4-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1468-3083.2011.04078.x","article-title":"Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial","volume":"26","author":"David","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key20180109222643_b5-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ophtha.2009.11.029","article-title":"Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial","volume":"117","author":"Avni","year":"2010","journal-title":"Ophthalmology"},{"key":"key20180109222643_b6-mmr-07-06-1723","first-page":"41","article-title":"Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial","volume":"35","author":"Silverman","year":"2008","journal-title":"J Rheumatol"},{"key":"key20180109222643_b7-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1517\/14728214.2011.563733","article-title":"Current and emerging medical therapies in the treatment of glaucoma","volume":"16","author":"Bagnis","year":"2011","journal-title":"Expert Opin Emerg Drugs"},{"key":"key20180109222643_b8-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.exer.2010.04.002","article-title":"Mechanisms of retinal ganglion cell injury and defense in glaucoma","volume":"91","author":"Qu","year":"2010","journal-title":"Exp Eye Res"},{"key":"key20180109222643_b9-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"12633","DOI":"10.1523\/JNEUROSCI.2801-06.2006","article-title":"Tumor necrosis factor-alpha mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma","volume":"26","author":"Nakazawa","year":"2006","journal-title":"J Neurosci"},{"key":"key20180109222643_b10-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/path.2858","article-title":"Retinal ganglion cell death is induced by microglia derived pro-inflammatory cytokines in the hypoxic neonatal retina","volume":"224","author":"Sivakumar","year":"2011","journal-title":"J Pathol"},{"key":"key20180109222643_b11-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ophtha.2007.01.036","article-title":"The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways","volume":"115","author":"Baudouin","year":"2008","journal-title":"Ophthalmology"},{"key":"key20180109222643_b12-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ophtha.2007.03.017","article-title":"Risk factors for incident open-angle glaucoma: the Barbados Eye Studies","volume":"115","author":"Leske","year":"2008","journal-title":"Ophthalmology"},{"key":"key20180109222643_b13-mmr-07-06-1723","first-page":"117","article-title":"Treatment principles and options","volume-title":"Terminology and Guidelines for Glaucoma","author":"Heijl","year":"2008","edition":"3rd edition"},{"key":"key20180109222643_b14-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2147\/PPA.S23780","article-title":"Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review","volume":"5","author":"Reardon","year":"2011","journal-title":"Patient Prefer Adherence"},{"key":"key20180109222643_b15-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1001\/archopht.1995.01100080061030","article-title":"A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol and betaxolol. International Dorzolamide Study Group","volume":"113","author":"Strahlman","year":"1995","journal-title":"Arch Ophthalmol"},{"key":"key20180109222643_b16-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.ophtha.2004.06.023","article-title":"Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term","volume":"111","author":"Baudouin","year":"2004","journal-title":"Ophthalmology"},{"key":"key20180109222643_b17-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1167\/iovs.03-1067","article-title":"Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study","volume":"45","author":"Pisella","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20180109222643_b18-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0149-2918(98)80055-6","article-title":"Comparison of the efficacy and safety of 2% dorzolamide and 0.5% betaxolol in the treatment of elevated intraocular pressure. Dorzolamide Comparison Study Group","volume":"20","author":"Rusk","year":"1998","journal-title":"Clin Ther"},{"key":"key20180109222643_b19-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00061198-200204000-00007","article-title":"Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension","volume":"11","author":"Katz","year":"2002","journal-title":"J Glaucoma"},{"key":"key20180109222643_b20-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1089\/108076803762718088","article-title":"Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension","volume":"19","author":"Feldman","year":"2003","journal-title":"J Ocul Pharmacol Ther"},{"key":"key20180109222643_b21-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1002\/jcp.22593","article-title":"CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver","volume":"226","author":"Cohen","year":"2011","journal-title":"J Cell Physiol"},{"key":"key20180109222643_b22-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1006\/excr.2001.5327","article-title":"The A3 adenosine receptor as a new target for cancer therapy and chemoprotection","volume":"269","author":"Fishman","year":"2001","journal-title":"Exp Cell Res"},{"key":"key20180109222643_b23-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/cc4893","article-title":"A3 adenosine receptors and mitogen-activated protein kinases in lung injury following in vivo reperfusion","volume":"10","author":"Matot","year":"2006","journal-title":"Crit Care"},{"key":"key20180109222643_b24-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1527-3466.2006.00227.x","article-title":"IB-MECA and cardioprotection","volume":"24","author":"Xu","year":"2006","journal-title":"Cardiovasc Drug Rev"},{"key":"key20180109222643_b25-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1124\/jpet.106.111351","article-title":"Cl-IB-MECA [2-chloro-N6-(3-iodobenzyl)adenosine-5\u2032-N-methylcarboxamide] reduces ischemia\/reperfusion injury in mice by activating the A3 adenosine receptor","volume":"319","author":"Ge","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"key20180109222643_b26-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"H2792","DOI":"10.1152\/ajpheart.01157.2004","article-title":"Role of adenosine A1 and A3 receptors in regulation of cardiomyocyte homeostasis after mitochondrial respiratory chain injury","volume":"288","author":"Shneyvays","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"key20180109222643_b27-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuint.2009.08.011","article-title":"The A3 adenosine receptor attenuates the calcium rise triggered by NMDA receptors in retinal ganglion cells","volume":"56","author":"Zhang","year":"2010","journal-title":"Neurochem Int"},{"key":"key20180109222643_b28-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1471-4159.2006.03900.x","article-title":"Balance of purines may determine life or death of retinal ganglion cells as A3 adenosine receptors prevent loss following P2X7 receptor stimulation","volume":"98","author":"Zhang","year":"2006","journal-title":"J Neurochem"},{"key":"key20180109222643_b29-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1167\/iovs.04-0915","article-title":"Selective upregulation of the A3 adenosine receptor in eyes with pseudoexfoliation syndrome and glaucoma","volume":"46","author":"Schl\u00f6tzer-Schrehardt","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20180109222643_b30-mmr-07-06-1723","first-page":"937","article-title":"Identification of the A3 adenosine receptor in rat retinal ganglion cells","volume":"12","author":"Zhang","year":"2006","journal-title":"Mol Vis"},{"key":"key20180109222643_b31-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.exer.2010.06.017","article-title":"Stimulation of the P2X7 receptor kills rat retinal ganglion cells in vivo","volume":"91","author":"Hu","year":"2010","journal-title":"Exp Eye Res"},{"key":"key20180109222643_b32-mmr-07-06-1723","first-page":"727","article-title":"Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101","volume":"28","author":"Bar-Yehuda","year":"2011","journal-title":"Int J Mol Med"},{"key":"key20180109222643_b33-mmr-07-06-1723","first-page":"3021","article-title":"Knockout of A3 adenosine receptors reduces mouse intraocular pressure","volume":"43","author":"Avila","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20180109222643_b34-mmr-07-06-1723","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/0165-6147(96)10002-X","article-title":"Adenosine receptor ligands: differences with acute versus chronic treatment","volume":"17","author":"Jacobson","year":"1996","journal-title":"Trends Pharmacol Sci"}],"container-title":["Molecular Medicine Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/mmr.2013.1413\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T23:36:45Z","timestamp":1515541005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/mmr.2013.1413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,4]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2013,4,4]]},"published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.3892\/mmr.2013.1413"],"URL":"https:\/\/doi.org\/10.3892\/mmr.2013.1413","relation":{},"ISSN":["1791-2997","1791-3004"],"issn-type":[{"value":"1791-2997","type":"print"},{"value":"1791-3004","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,4]]}}}